Our Brands
Bio Preventive Medicine Corp. (BPM)
Bio Preventive Medicine Corp. (BPM) is a Taiwan-based, clinical‑stage biotech and in vitro diagnostics company that focuses on early detection and prevention of disease using high‑value, biomarker‑based molecular diagnostic products. Founded in 2014 as a spin‑off from Taiwan’s Industrial Technology Research Institute (ITRI) and headquartered in the Hsinchu/Zhubei area, BPM develops precision diagnostics mainly for chronic diseases and oncology, with a particular emphasis on diabetic kidney disease.
The company’s flagship product line, DNlite (including DNlite‑IVD103), is a non‑invasive urinary test series designed to monitor progression and predict outcomes in diabetic nephropathy, providing clinicians with an earlier signal of renal deterioration than traditional markers. BPM positions itself as a leading renal biomarker company and offers a total solution concept that covers prevention, screening, and longitudinal monitoring of chronic diseases and cancers, while pursuing regulatory approvals such as EU IVDR and partnering with pharmaceutical and diagnostic companies for translational research and global commercialization.
Benefits
Liquid ready-to-use
- All samples are provided in a user-friendly, liquid ready-to-use format significantly reducing preparation time and the risk of pipetting errors
Integration with software
- Pairs with Acusera 24.7 for automated QC rules, peer group data, and ISO 15189 compliance reporting